DexCom, Inc. (NASDAQ:DXCM) Director Sells $24,756.16 in Stock

DexCom, Inc. (NASDAQ:DXCM) Director Bridgette P. Heller sold 352 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $70.33, for a total value of $24,756.16. Following the completion of the sale, the director now directly owns 22,997 shares in the company, valued at approximately $1,617,379.01. The trade was a 1.51 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

DexCom Price Performance

Shares of DexCom stock opened at $73.80 on Friday. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a market cap of $28.84 billion, a PE ratio of 51.61, a P/E/G ratio of 2.30 and a beta of 1.28. The business has a 50 day moving average of $83.33 and a 200 day moving average of $76.95. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on DXCM. Citigroup raised their price target on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Morgan Stanley raised their price target on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $99.82.

Hedge Funds Weigh In On DexCom

Hedge funds and other institutional investors have recently made changes to their positions in the business. Versant Capital Management Inc bought a new position in shares of DexCom during the fourth quarter valued at approximately $25,000. Private Trust Co. NA grew its stake in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares during the period. Optiver Holding B.V. purchased a new stake in DexCom in the fourth quarter worth $33,000. TD Private Client Wealth LLC grew its stake in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after purchasing an additional 167 shares during the period. Finally, Larson Financial Group LLC grew its stake in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after purchasing an additional 137 shares during the period. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.